The Phase II trial, being conducted in the UK, is a multi-center, randomized, double-blind, placebo-controlled, dose response, factorial 12-arm parallel group study evaluating 120 patients equally randomized to
If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure against bio-terrorism and emerging infectious diseases such as Ebola or Marburg, and dengue. The company
The submission is based on an analysis that included 138 patients with chronic lymphocytic leukemia (CLL) who showed limited or no response to both fludarabine and alemtuzumab treatment
According to the company, duloxetine-treated patients showed greater reductions from baseline on the primary endpoint, the 24-hour average pain score on the Brief Pain Inventory (BPI), compared with
According to the company, Advance PTX is one of the first PTA balloon catheters to be coated with paclitaxel, an antiproliferative drug that has been used successfully to
The 360 patient, active comparator trial compared the efficacy and safety of NP-1 against both gabapentin and placebo. The first primary endpoint was the change in pain intensity
The investors have agreed to purchase the shares at a purchase price of $9.73 per share resulting in gross proceeds of approximately $45.5 million to Pharmasset, before deducting
Terrance Gregg, DexCom’s president and CEO, is also purchasing 150,000 additional shares of common stock in this offering at a price per share of $3.12, which represents the
Under the transaction, Exact retained exclusive worldwide rights to its colorectal cancer screening and stool-based DNA testing intellectual property, and will receive a share of Genzyme’s sublicensing income
As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has received a 180-day period of marketing exclusivity.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.